Biopharma Week in Review - October 21, 2024
266 Views22 Oct 2024 23:20
Issuer-paid
Last week, LBPH was acquired, providing a boost to comps PRAX, MRNS, JAZZ, and DRUG. Biopharma M&A may start seeing an uptick after a slow summer.
What is covered in the Full Insight:
- Biopharma M&A Activities
- RNA Editing and Regulatory Pathways
- Clinical Updates: EXEL, JSPR, JAZZ, MGTX, AURA
- Regulatory and Trial Setbacks: NVAX, GILD
- Market Performance and Outlook
SUMMARY
(Sign Up to Access)Full Insight
(Paid Plans Only, 8-minute read)
Top Unpaywalled Insights
More »Discussions
(Paid Plans Only)